Kishan J Pandya

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642 USA
    Breast Cancer Res Treat 83:87-9. 2004
  2. ncbi request reprint Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285)
    Kishan J Pandya
    University of Rochester Cancer Center, Rochester, NY 14642, USA
    Oncology 66:118-25. 2004
  3. pmc Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial
    Kishan J Pandya
    University of Rochester Cancer Center Community Clinical Oncology Program Research Base, University of Rochester Cancer Center, Rochester, NY 14642, USA
    Lancet 366:818-24. 2005
  4. ncbi request reprint Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)
    Kishan J Pandya
    University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Am J Clin Oncol 30:113-25. 2007
  5. ncbi request reprint A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    J Thorac Oncol 2:1036-41. 2007
  6. pmc Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer
    Yuhchyau Chen
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 80:1358-64. 2011
  7. doi request reprint Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer
    Kishan J Pandya
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Lung Cancer 67:330-8. 2010
  8. pmc Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer
    Yuhchyau Chen
    Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 71:407-13. 2008
  9. doi request reprint Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: a model for low-dose chemotherapy radiosensitization
    Hong Zhang
    Departments of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    J Thorac Oncol 3:563-8. 2008
  10. doi request reprint Advances in personalized therapy for lung cancer
    Eric S Kim
    University of Rochester, James P Wilmot Cancer Center, The Department of Medicine, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    Expert Opin Med Diagn 7:475-85. 2013

Detail Information

Publications12

  1. ncbi request reprint Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642 USA
    Breast Cancer Res Treat 83:87-9. 2004
    ..Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further...
  2. ncbi request reprint Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285)
    Kishan J Pandya
    University of Rochester Cancer Center, Rochester, NY 14642, USA
    Oncology 66:118-25. 2004
    ..To compare the efficacy and the toxicity of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer. Patients and..
  3. pmc Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial
    Kishan J Pandya
    University of Rochester Cancer Center Community Clinical Oncology Program Research Base, University of Rochester Cancer Center, Rochester, NY 14642, USA
    Lancet 366:818-24. 2005
    ..We undertook a randomised, double-blind, placebo-controlled, multi-institutional trial to assess the efficacy of gabapentin in controlling hot flashes in women with breast cancer...
  4. ncbi request reprint Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)
    Kishan J Pandya
    University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Am J Clin Oncol 30:113-25. 2007
    ....
  5. ncbi request reprint A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    Kishan J Pandya
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    J Thorac Oncol 2:1036-41. 2007
    ..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer...
  6. pmc Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer
    Yuhchyau Chen
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 80:1358-64. 2011
    ....
  7. doi request reprint Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer
    Kishan J Pandya
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Lung Cancer 67:330-8. 2010
    ..In the follow-up phase, TTP and OS time were similar. Adding zoledronic acid to docetaxel/carboplatin in advanced stage NSCLC patients was well tolerated, but provided little to no effect on disease progression endpoints...
  8. pmc Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer
    Yuhchyau Chen
    Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 71:407-13. 2008
    ..We report the toxicity profile and pharmacokinetic data of a schedule-dependent chemoradiation regimen using pulsed low-dose paclitaxel for radiosensitization in a Phase I study for inoperable non-small-cell lung cancer...
  9. doi request reprint Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: a model for low-dose chemotherapy radiosensitization
    Hong Zhang
    Departments of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    J Thorac Oncol 3:563-8. 2008
    ..Given our unique results, we analyzed the tumor response kinetics and conducted a statistical modeling of tumor response to characterize this regimen...
  10. doi request reprint Advances in personalized therapy for lung cancer
    Eric S Kim
    University of Rochester, James P Wilmot Cancer Center, The Department of Medicine, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    Expert Opin Med Diagn 7:475-85. 2013
    ..This review provides an overview of clinically approved strategies to personalize treatment for lung cancer as well as evolving strategies in various stages of clinical development...
  11. doi request reprint Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma
    David M Brizel
    Department of Radiation Oncology, Duke University, Durham, NC, USA
    J Clin Oncol 26:2489-96. 2008
    ..This study assessed the efficacy and safety of palifermin in patients receiving concurrent chemoradiotherapy for advanced head and neck squamous cell carcinoma...
  12. doi request reprint Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer
    Arkadiusz Z Dudek
    University of Minnesota Comprehensive Cancer Center, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:394-9. 2008
    ..Pemetrexed is synergistic with gemcitabine in preclinical models of non-small cell lung cancer (NSCLC). The optimal dose and utility of gemcitabine and pemetrexed was evaluated in a dose-escalating study...